Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MNKD 
MannKind Corp (MNKD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: MNKD (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.38
1 Year Target Price $10.38
| 6 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 42.84% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.73B USD | Price to earnings Ratio 56.3 | 1Y Target Price 10.38 |
Price to earnings Ratio 56.3 | 1Y Target Price 10.38 | ||
Volume (30-day avg) 7 | Beta 0.81 | 52 Weeks Range 3.38 - 7.48 | Updated Date 11/7/2025 |
52 Weeks Range 3.38 - 7.48 | Updated Date 11/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-11 | When - | Estimate 0.0213 | Actual 0.07 |
Profitability
Profit Margin 9.32% | Operating Margin (TTM) 22.86% |
Management Effectiveness
Return on Assets (TTM) 9.95% | Return on Equity (TTM) - |
Valuation
Trailing PE 56.3 | Forward PE 34.36 | Enterprise Value 1552324559 | Price to Sales(TTM) 5.51 |
Enterprise Value 1552324559 | Price to Sales(TTM) 5.51 | ||
Enterprise Value to Revenue 5.14 | Enterprise Value to EBITDA 19.62 | Shares Outstanding 307070281 | Shares Floating 301229804 |
Shares Outstanding 307070281 | Shares Floating 301229804 | ||
Percent Insiders 1.64 | Percent Institutions 55.74 |
Upturn AI SWOT
MannKind Corp
Company Overview
History and Background
MannKind Corporation was founded in 1991. It is a biopharmaceutical company focused on the discovery, development, and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. A major milestone was the FDA approval of Afrezza, their inhaled insulin product.
Core Business Areas
- Inhaled Therapeutics: Focuses on developing and commercializing inhaled drugs, primarily for diabetes and pulmonary diseases.
- Afrezza: MannKind's flagship product, Afrezza, is an inhaled rapid-acting insulin used to control blood sugar in adults with diabetes.
- Tyvaso DPI: A dry powder inhalation formulation of treprostinil, developed with United Therapeutics, for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Leadership and Structure
Michael Castagna serves as the Chief Executive Officer. The company has a typical corporate structure with departments for R&D, commercial operations, finance, and administration.
Top Products and Market Share
Key Offerings
- Afrezza: Afrezza is a rapid-acting inhaled insulin. The market share is estimated to be small, and not readily available, with limited usage due to patient and physician concerns about inhaled insulin. Competitors are Novo Nordisk (NovoLog), Eli Lilly (Humalog), and Sanofi (Apidra).
- Tyvaso DPI: A dry powder inhalation formulation of treprostinil, developed with United Therapeutics. Competitors include liquid or nebulized versions of treprostinil and other pulmonary hypertension medications.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The diabetes and pulmonary disease markets are substantial and growing.
Positioning
MannKind is positioned as an innovative company specializing in inhaled drug delivery. Its competitive advantage lies in its Technosphere technology, which enables rapid absorption of drugs through the lungs.
Total Addressable Market (TAM)
The total addressable market for insulin and pulmonary hypertension medications is substantial, potentially reaching billions of dollars. MannKind is positioned to capture a share of these markets with its differentiated products, like Tyvaso DPI (manufactured by MannKind), particularly if uptake of Afrezza increases.
Upturn SWOT Analysis
Strengths
- Technosphere technology platform
- Partnership with United Therapeutics for Tyvaso DPI
- Focus on inhaled drug delivery
- FDA-approved Afrezza
Weaknesses
- Limited market penetration of Afrezza
- Dependence on a limited number of products
- History of financial losses
- Relatively small size compared to competitors
Opportunities
- Expansion of Afrezza into new markets and indications
- Development of new inhaled therapeutic products
- Strategic partnerships and collaborations
- Increasing prevalence of diabetes and pulmonary diseases
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and clinical trial risks
- Pricing pressures and reimbursement challenges
- Adverse events or safety concerns related to their products
Competitors and Market Share
Key Competitors
- NVO
- LLY
- SANOY
- UTHR
Competitive Landscape
MannKind faces intense competition from larger, more established pharmaceutical companies. Its competitive advantage lies in its innovative Technosphere technology, but it faces challenges in gaining market share due to limited resources and established competitors.
Growth Trajectory and Initiatives
Historical Growth: MannKind has experienced fluctuating growth, largely dependent on the success of Afrezza and the progression of its pipeline. The Tyvaso DPI collaboration provides a more consistent revenue stream.
Future Projections: Future growth is projected to come from increased sales of Afrezza, growth from Tyvaso DPI, and the development and commercialization of new inhaled products. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include expanding the sales force for Afrezza, focusing on key patient populations, and advancing clinical trials for new indications.
Summary
MannKind is a biopharmaceutical company specializing in inhaled drug delivery. Afrezza's market penetration has been a challenge, but the Tyvaso DPI partnership represents a significant revenue stream. The company's future hinges on the successful commercialization of its products and the expansion of its pipeline. The company must overcome competition from larger pharmaceutical companies and address financial stability.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q), Company Investor Relations, Analyst Reports, Publicly Available Market Data
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and based on available data. Financial data should be verified through official company filings. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MannKind Corp
Exchange NASDAQ | Headquaters Danbury, CT, United States | ||
IPO Launch date 2004-07-28 | CEO & Director Dr. Michael E. Castagna Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 403 | Website https://www.mannkindcorp.com |
Full time employees 403 | Website https://www.mannkindcorp.com | ||
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company's product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.